We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Biosimilar Monoclonal Antibody Guidance Favorable to Developers
EMA Biosimilar Monoclonal Antibody Guidance Favorable to Developers
December 3, 2010
The European Medicines Agency’s (EMA) newly released draft guidance on monoclonal antibody-based biosimilars appears to lessen the regulatory hurdles for biosimilar developers, analysts say.